A 10-year Review of TB Notifications and Mortality Trends Using a Joint Point Analysis in Zambia - a High TB burden country

Lungu, Patrick; Kasapo, Clara C; Mihova, Reford; Chimzizi, Rhehab; Sikazwe, Lyapa; Banda, Isaac; Mucheleng’anga, Luchenga Adam; Chanda‐Kapata, Pascalina; Kapata, Nathan; Zumla, Alimuddin; Mwaba, Peter

doi:10.1016/j.ijid.2022.03.046

Cited by 8 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study on DR-TB in the northern region of Zambia found a prevalence of 53% MDR-TB, 32% rifampicin mono-resistance and 1.7% pre-XDR-TB [34]. Another decade-long (2010-2022) retrospective study of TB notifications and mortality trends showed an increase in DR-TB cases, with an average annual rate of 25.0 [69]. Statistics from these previous studies reflect an increase in DR-TB even when compared to the findings in this study.…”

Section: Discussionmentioning

confidence: 99%

First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia

et al. 2023

View full text Add to dashboard Cite

Background: Drug-resistant tuberculosis has continued to be a serious global health threat defined by complexity as well as higher morbidity and mortality wherever it occurs, Zambia included. However, the paucity of information on drug-susceptibility patterns of both first-line and second-line anti-tuberculosis (anti-TB) drugs, including the new and repurposed drugs used in the management of drug-resistant tuberculosis in Zambia, was the major thrust for conducting this study. Methods: A total of 132 bacteriologically confirmed TB isolates were collected from patients with pulmonary TB during the period from April 2020 to December 2021 in Southern and Eastern Provinces of Zambia. Drug-resistance profiles were determined according to four first-line and five second-line anti-TB drugs. Standard mycobacteriological methods were used to isolate and determine phenotypic drug susceptibility. Data on the participants’ social–demographic characteristics were obtained using a pre-test checklist. Results: Overall, the prevalence of resistance to one or more anti-TB drugs was 23.5% (31/132, 95% CI: 16.5–31.6%). A total of 9.8% (13/132, 95% CI: 5.3–16.2%) of the patients had multidrug-resistant TB and 1.2% were new cases, while 25.5% had a history of being previously treated for TB. Among those with mono-resistant TB strains, isoniazid (INH) resistance was the highest at 9.8% (13/132, 95% CI: 5.3–16.2%). Two (2/31) (6.5%) XDR-TB and one (1/31) (3.2%) pre-XDR-TB cases were identified among the MDR-TB patients. Previously treated patients were 40 times more likely (OR; 40.3, 95% CI: 11.1–146.5%) to have drug-resistant TB than those who had no history of being treated for TB. Conclusion: This study has established a high rate of multidrug-resistant TB and has further identified both pre-XDR- and XDR-TB. There is a need to intensify surveillance of MDR- and XDR-TB to inform future guidelines for effective treatment and monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Other, qualitative studies early in the pandemic in Zambia indicated that service availability and fear of contracting COVID-19 during clinic visits were major barriers to patients receiving TB services, 5 and several Ministry of Health and hospital policies were implemented throughout 2020 to bolster TB services. 22 Despite these limitations, this study provides the first quantitative evaluation of TB service disruption in the largest TB clinic in urban Zambia. Our results clearly demonstrate the immediate shock experienced by TB services at a large urban TB clinic at a tertiary hospital in Lusaka, the relative resiliency of the clinic, and yet the long road ahead to full recovery.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on Tuberculosis Testing and Treatment at a Tertiary Hospital in Zambia

Rosser

Phiri

Bramante

et al. 2023

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Globally, tuberculosis (TB) testing and treatment have declined dramatically during the COVID-19 pandemic. We quantified the change in TB visits, testing, and treatment compared with a 12-month pre-pandemic baseline at the national referral hospital’s TB Clinic in Lusaka, Zambia, in the first year of the pandemic. We stratified the results into early and later pandemic periods. In the first 2 months of the pandemic, the mean number of monthly TB clinic visits, prescriptions, and positive TB polymerase chain reaction (PCR) tests decreased as follow: −94.1% (95% CI: −119.4 to −68.8%), −71.4% (95% CI: −80.4 to −62.4%), and −73% (95% CI: −95.5 to −51.3%), respectively. TB testing and treatment counts rebounded in the subsequent 10 months, although the number of prescriptions and TB-PCR tests performed remained significantly lower than pre-pandemic. The COVID-19 pandemic significantly disrupted TB care in Zambia, which could have long-lasting impacts on TB transmission and mortality. Future pandemic preparedness planning should incorporate strategies developed over the course of this pandemic to safeguard consistent, comprehensive TB care.

show abstract

“…Comparable studies across Africa reported a similar significant reduction in TB case notifications with more notifications in men with a few reporting a higher burden in women and children [10] , [11] . Despite this, as the country strives to improve TB services being offered, it is important that the excess burden experienced by men be taken into consideration [18] .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of treatment outcomes among adult patients diagnosed with tuberculosis in Ghana: A 10 year retrospective review

Puplampu,

Kyeremateng,

Asafu-Adjaye

et al. 2024

IJID Regions

View full text Add to dashboard Cite

A 10-year Review of TB Notifications and Mortality Trends Using a Joint Point Analysis in Zambia - a High TB burden country

Cited by 8 publications

References 19 publications

First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia

First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia

Impact of the COVID-19 Pandemic on Tuberculosis Testing and Treatment at a Tertiary Hospital in Zambia

Evaluation of treatment outcomes among adult patients diagnosed with tuberculosis in Ghana: A 10 year retrospective review

Contact Info

Product

Resources

About